Monthly GP Update: February 2026
Feb 9, 2026
By now, your Medicaid, PHS/340B, and Medicare calculations for Q4/December 2025 should be wrapped up, which means it’s about time to get started on your next monthly calculations!
Things that are due in the upcoming 45 days include:
Q4 2025 NFAMP (February 16)
TRICARE refunds/rebates (February 19)
PHS/340B pricing to HRSA (February 27) and to wholesalers/distributors (March 15)
Monthly AMP submitted and certified in MDP (March 2)
Payment for the Medicare Manufacturer Discount Program Part D rebates via MPP (March 11)
(Remember, our online calendar is a great resource for tracking deadlines and events.)
In other GP news:
CMS announced the next round of drugs selected for Medicare Drug Price Negotiations and issued a Fact Sheet that provides more information for this round and information on the potential for “renegotiation” of those drugs previously selected.
In the most recent news surrounding the PHS/340B Program, Senator Bill Cassidy (R) of Louisiana and chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, has sent a letter to Apexus, requesting records related to their activities as the PHS/340B Prime Vendor. Senator Cassidy has been a vocal critic of many components of the program and in the latest Press Release announcing the letter, he said, “In light of Apexus’s role as the current 340B prime vendor, and given questions raised into its business practices, I am requesting information and data to better understand how Apexus generates its revenue and designs its commercial offerings related to the 340B program.” This program continues to be interesting!
As always, this information is intended to provide general guidance and to provide general industry information and/or context for potential activity in the near future. Some of it may not apply to your company and there may be other requirements that are not included here. If you have any questions on these matters or about Government Pricing in general, feel free to reach out at any time.